Side-by-side · Research reference

GDF-8vsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/48 cited

BPhase 3HUMAN-REVIEWED14/43 cited

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

GDF-8

Sermorelin

Primary target

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Pituitary GHRH receptorWalker 1994

Pathway

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Yes — short pulse preserves feedback

Origin

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

GDF-8

Sermorelin

Clinical use

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

—

Inhibition strategies

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

—

VLP immunogen (MS2.87-97)

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

—

Dual immunization (MSTN + Activin A)

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

—

Gene editing outcomes

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

—

Standard dose

—

100–500 mcg per injectionMolteno 2013

Frequency

—

Once daily, pre-sleep

Lower / starter dose

—

100 mcg per dose

Evidence basis

—

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Duration

—

8–12 weeks per cycle

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep, fasted preferred

Half-life

—

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

03Metabolic / Fat Loss Evidence

Parameter

GDF-8

Sermorelin

Primary mechanism

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

—

Human genetic evidence

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

—

Animal model outcomes

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

—

Adipose-muscle crosstalk

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

—

Metabolic benefits

Improved metabolic health in genetic MSTN null modelsJacquez 2026

—

Age-related effects

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

—

04Side Effects & Safety

Parameter

GDF-8

Sermorelin

Genetic null phenotype

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

—

Antibody cross-reactivity risk

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

—

VLP immunotherapy safety

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

—

Echocardiography

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

—

Pleiotropic effects (gene editing)

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

—

Assay variability

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

—

Injection site reaction

—

Mild erythema, transient pain

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Glucose handling

—

Generally neutral

Absolute Contraindications

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

GDF-8

Sermorelin

1. Research context only

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Inhibition strategies

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

SQ — abdomen or thigh. Rotate sites.

3. VLP immunization protocol (animal model)

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

Pre-sleep, fasted.

4. Gene editing considerations

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

GDF-8

— no documented stacks

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994